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The aim of this work was to optimize the preparative process of quercetin loaded casein 
nanoparticles as well as to evaluate the pharmacokinetics of this flavonoid when 
administered orally in Wistar rats. Nanoparticles were obtained by coacervation after 
the incubation of casein, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and quercetin in an 
aqueous environment. Then, nanoparticles were purified and dried. The resulting 
nanoparticles displayed a size of 200 nm with a negative zeta potential and a payload of 
about 32 μg/mg. Release studies showed a zero-order kinetic, suggesting a mechanism 
based on erosion of the nanoparticle matrix. For the pharmacokinetic study, quercetin 
was orally administered to rats as a single dose of 25 mg/kg. Animals treated with 
quercetin-loaded casein nanoparticles displayed higher plasma levels than those 
observed in animals receiving the solution of the flavonoid (control). Thus, the relative 
oral bioavailability of quercetin when administered as casein nanoparticles (close to 
37%)  was found to be about 9-times higher than the oral solution of the flavonoid in a 
mixture of PEG 400 and water. In summary, the combination of casein and 2-
hydroxypropyl-β-cyclodextrin produces nanoparticles that may be a good option to load 
quercetin for both nutraceutical and pharmaceutical purposes. 
 




Quercetin (3,3’,4’,5,7-pentahydroxyflavone) is a naturally occurring flavonoid and one 
of the most potent antioxidants of plant origin (Anand David et al., 2016; Zhang M. et 
al., 2011). Chronic intake of quercetin may be associated with a decreased risk of 
coronary heart disease (Patel et al., 2018; Perez-Vizcaino et al., 2006) and other 
degenerative conditions, including cancer (Kashyap et al., 2016; Rauf et al., 2018), 
diabetes (Bule et al., 2019; Chen et al., 2016), and neurodegenerative disorders (Barreca 
et al., 2016; Dajas et al., 2015). The median daily intake of quercetin within a typical 
Western diet has been estimated as about 10 mg and the major sources would be tea, 
red wine, fruits, and vegetables (Egert et al., 2018). In some countries, quercetin is 
available as a dietary supplement with recommended daily doses ranging from 200 to 
1200 mg (Harwood et al., 2007). In a similar way, it has been proposed the use of 
quercetin as a nutraceutical for functional foods within a concentration range of 10–125 
mg/serving (Harwood et al., 2007; Russo et al., 2012). 
However, when orally administered, quercetin shows a very low bioavailability (less than 
10% in rats, 4% in dogs and even 1% in humans) (Khaled et al., 2003; Reinboth et al., 
2010). This drawback would be related to the low solubility of the aglycone form (around 
10 mg/L in water) (Smith et al., 2011) as well as to the intense presystemic metabolism 
suffering by this flavonoid in the gut mucosa. In fact, quercetin would be substrate of 
the efflux pumps (e.g., intestinal P-glycoprotein) and cytochrome P-450 (CYP) 
isoenzymes and transferases located both in the gastrointestinal tract and in the liver 
(Babu et al., 2013; Limtrakul et al., 2005; Wang et al., 2014). As a result of this 
metabolism, the glucuronide and sulphate derivatives of quercetin would be the major 
circulating compounds in plasma (Lodi et al., 2009; Nakamura et al., 2018). Apart from 
its considerable metabolism, quercetin is chemo- and thermo-labile and rapidly 
degraded when exposed to alkaline media, light or warm temperature (Scalia and 
Mezzena, 2009).  
In order to enhance the oral bioavailability of quercetin, different strategies have been 
tested, including the synthesis of analogues of the flavonoid (Iacopetta et al., 2017; Kim 
et al., 2009) and the co-administration with P-gp inhibitors (i.e., piperine) (Rinwa and 
Kumar, 2017). In a similar way, the use of nanocarriers has been suggested to promote 
the oral absorption of quercetin. Some authors have proposed, inter alia, 
nanosuspensions (Gao et al., 2011), self-emulsifying delivery systems (Jain et al., 2014), 
nanoemulsions (Karadag et al., 2013), liposomes (Caddeo et al., 2019), and 
nanoparticles (de Oliveira Pedro et al., 2018; Li et al., 2009; Moreno et al., 2017).  
Another interesting alternative would be the use of casein-based nanoparticles. These 
nanoparticles can be prepared by a simple coacervation process, in an aqueous 
environment without using any type of organic solvent or toxic reagent (Penalva et al., 
2015). The resulting nanoparticles show a certain capability to reach the epithelium 
surface of the gut mucosa (Peñalva et al., 2018), facilitating the absorption of the loaded 
compound. Moreover, casein is the main protein in raw milk (about 80%) and one of the 
most commonly used by the industry for supplementation purposes (Hoffman and 
Falvo, 2004). This fact would facilitate the use of casein-based nanoparticles to develop 
pharmaceutical and nutraceutical products or functional foods. 
Therefore, the aim of this work was to optimize the preparative process of quercetin-
loaded casein nanoparticles as well as to evaluate their capabilities to promote the oral 
absorption and bioavailability of quercetin in Wistar rats. In this context, and in order to 
minimize the pre-systemic metabolism of quercetin, 2-hydroxylpropyl-β-cyclodextrin 
was associated with casein nanoparticles in order to disturb the effect of both the 
intestinal efflux pumps and the cytochrome P450 enzymatic complex (Buggins et al., 
2007; Takizawa et al., 2013; Zhang Y. et al., 2011). 
 
 
2. Materials and methods 
2.1. Reagents 
Sodium caseinate was obtained from ANVISA (Madrid, Spain). Quercetin, lysine, 2-
hydroxy-propyl-β-cyclodextrin (HP-β-CD), mannitol, chlorzoxazone, calcium chloride, 
poly(ethylene glycol) 400 (PEG 400), and tween 20 were from Sigma-Aldrich (Germany). 
Ethanol, methanol, acetic acid and acetonitrile (HPLC grade) were from Merck 
(Darmstadt, Germany). All reagents and chemicals used were of analytical grade.  
 
2.2. Preparation of quercetin-loaded casein nanoparticles 
Nanoparticles were prepared by simple coacervation procedure followed by a 
purification step by ultrafiltration and subsequent drying by Spray-drying (Penalva et al., 
2015). 
Briefly, 1 g sodium caseinate, 90 mg lysine (as stabilizer (Penalva et al., 2015)) and a 
variable amount of HP-β-CD were dissolved in 75 mL purified water. In parallel, 35 mg 
quercetin were dissolved in 3 mL absolute ethanol and added under magnetic stirring to 
the casein solution. Under magnetic stirring, nanoparticles were formed by the addition 
of 40 mL of an aqueous solution of calcium chloride 0.8% w/v. The resulting suspension 
was purified by ultrafiltration through a polysulfone membrane cartridge of 50kDa pore 
size (Medica SPA, Italy). Finally, 30 mL of an aqueous solution of mannitol (100 mg/mL) 
were added to the suspension of casein nanoparticles and the mixture was dried in a 
Buchi Mini Spray Drier B-290 apparatus (BuchiLabortechnik AG, Switzerland) under the 
following experimental conditions: (i) inlet temperature: 90°C, (ii) outlet temperature: 
45-50°C, (iii) air pressure: 2-5 bar, (iv) pumping rate: 2-6 mL/min, (v) aspirator: 100% and 
(vi) air flow: 900 L/h. The resulting nanoparticles were named Q-HPCD-NP. 
On the other hand, nanoparticles in the absence of the cyclodextrin were also prepared 
(Q-NP). In this case, sodium caseinate (1 g), lysine (90 mg) and an ethanol solution of 
quercetin (35 mg in 3 mL) were dissolved in 75 mL purified water. Then, nanoparticles 
were obtained by the addition of 40 mL of a solution of calcium chloride in purified water 
(0.8% w/v). The resulting nanosuspensions were purified and dried as described above. 
Empty nanoparticles were also prepared as described above but either in the absence 
of the oligosaccharide and quercetin (NP) or in the absence of the flavonoid (HPCD-NP). 
 
2.3. Preparation of quercetin conventional formulations 
For in vivo studies, two conventional formulations of quercetin were used. The first 
consisted on a solution of the polyphenol in a mixture of PEG 400 and water (6:4 by vol.). 
For this purpose, 62.5 mg quercetin were dissolved in 6 mL PEG 400 under magnetic 
stirring. Then 4 mL purified water were added and the final mixture was agitated in 
darkness conditions for 10 min. This formulation was identified as Q-sol. 
The second formulation was an extemporary suspension of quercetin in purified water 
(Q-susp). Briefly, 62.5 mg quercetin was dispersed in 10 mL purified water under 
magnetic agitation for 10 min. The size of the resulting suspension was 15.5 ± 4.3 μm. 
The suspension was used after inspection for absence of aggregates. 
  
2.4. Characterization of nanoparticles 
2.4.1. Size, zeta potential and morphology 
The mean hydrodynamic diameter and the zeta potential of nanoparticles were 
determined by photon correlation spectroscopy (PCS) and electrophoretic laser Doppler 
anemometry, respectively, using a Zetaplus apparatus (Brookhaven Instrument 
Corporation, USA). The diameter of the nanoparticles was determined after dispersion 
in ultrapure water (1:10) and measured at 25°C with a scattering angle of 90°. The zeta 
potential was measured after dispersion of the dried nanoparticles in 1 mM KCl solution. 
The morphology and shape of nanoparticles was examined using a field emission 
scanning electron microscope (FE-SEM) in a Zeiss DSM940 digital scanning electron 
microscope (Oberkochen, Germany) coupled with a digital image system (Point 
Electronic GmBh, Germany). Prior to the microscopy analysis, particles were washed to 
remove mannitol. For this purpose, spray-dried nanoparticles were resuspended in 
distilled water and centrifuged at 27,000 x g for 10 min. Then, the supernatants were 
discarded and the pellets were mounted on copper grids. Finally, the pellet was shaded 
with an amalgam of gold/palladium for fifteen seconds using a sputter coater (K550X 
Emitech, Ashford, UK). 
The yield of the process was calculated by gravimetry as described previously (Peñalva 
et al., 2018). 
 
2.4.2. Quercetin analysis 
The amount of quercetin loaded into the nanoparticles was quantified by HPLC-UV 
following an analytical method previously published with minor modifications (Iacopini 
et al., 2008). Analysis were carried out in an Agilent model 1100 series LC and a diode-
array detector set at 370 nm. The chromatographic system was equipped with a 
reversed-phase 150 mm x 2.1 mm C18 Alltima column (particle size 5 μm; Altech, USA) 
and a Gemini C18 precolumn (particle size 5 μm; Phenomenex, CA, USA). The mobile 
phase, pumped at 0.25 mL/min, consisted of a mixture of methanol, water and acetic 
acid in gradient conditions. The column was placed at 40°C and the injection volume was 
10 µL. Calibration curves were designed over the range of 0.3-100 μg/mL. The limit of 
quantification was calculated to be 0.35 μg/mL. 
For analysis, 10 mg nanoparticles were dispersed in 1 mL water and centrifuged at 
30,500 xg for 20 min. The supernatants were analyzed in order to determine the amount 
of free quercetin (not encapsulated). The amount of quercetin loaded in the 
nanoparticles was calculated by subtracting from the theoretical amount of quercetin, 
the amount of drug found in the supernatant (equation 1).  The encapsulation efficiency 
(EE) was calculated with equation 2. Each sample was assayed by triplicate and the 
results were expressed as the amount of quercetin (in μg) per mg nanoparticles. 
 
Quercetin loaded (μg/mg) = (Qt-Qs)/Wp [Eq. 1] 
EE (%) = ((Qt-Qs))/(Qt)×100     [Eq. 2] 
in which Qt is the total theoretical amount of quercetin in the formulations, Qs 
corresponds to the amount of quercetin quantified in the supernatants and Wp the 
amount of protein quantified as described above. 
 
2.5. In vitro release studies 
Release experiments were conducted at 37°C using simulated gastric (SGF, pH 1.2) and 
intestinal (SIF, pH 6.8) fluids (European Pharmacopoeia, 2013). In order to fulfil sink 
conditions, Tween® 20 (0.5% w/v) was added to both media. The studies were 
performed under agitation in a slide-A-Lyzer® Dialysis cassette 10.000 MWCO (Thermo 
scientific, Rockford, IL, USA).  
For the study, 2 mg of quercetin loaded in casein nanoparticles were dispersed in 5 mL 
of purified water and introduce in the cassette, which was then placed into a vessel 
containing 500 mL of SGF for 2 hours. After this time, the same cassette was removed 
from the SGF and introduced in a second vessel with 500 mL SIF until the end of the 
experiment. At different time points, samples of 1 mL were collected and filtered to 0.45 
µm (Filter nylon, Thermo scientific, Rockford, USA) before quantification. At each 
sampling time, the withdrawn volume was replaced with fresh fluid (gastric or intestinal 
simulated fluids). 
The amount of quercetin released from the formulations was quantified by HPLC. 
Calibration curves of quercetin were prepared in both release media over the range of 
0.16-6 µg /mL (R2 > 0.99). 
  
2.5.1. Analysis of release data 
In order to ascertain the drug release mechanism, data obtained from the in vitro 
release experiments were fitted to Korsmeyer-Peppas and zero-order models. The 
Korsmeyer–Peppas model (Ritger and Peppas, 1987) is a simple semi-empirical model 
which exponentially relates drug release with the elapsed time (equation 3). 
 
Mt/M∞ =  KKP tn     [Eq. 3] 
Where Mt/M∞ is the drug release frac on at me t, KKP is a constant incorporating the 
structural and geometric characteristics of the matrix and n is the release exponent 
indicative of the drug release mechanism. The value of ”n” indicates the mechanism of 
the release (Ritger and Peppas, 1987). If the value is around 0.5, the mechanism is Case 
I (Fickian) diffusion, and a value between 0.5 and 0.89 indicates anomalous (non-Fickian) 
diffusion suggesting a combination of mechanisms diffusion and erosion. Values of “n” 
between 0.89 and 1 indicate Case II transport, which involves a release mechanism ruled 
by erosion/relaxation of the matrix. 
 
Data obtained from the in vitro release experiments were also fitted to a zero-order 
kinetic equation (equation 4). This model is used for systems where the matrix releases 
the same amount of drug by unit of time (Costa and Sousa Lobo, 2001). 
Mt/M∞ =  KZO t     [Eq. 4] 
 
Where Mt/M∞ is the drug release fraction at time t, and KZO is the zero order release 
constant. 
To fit the experimental data to the previous equation, only one portion of the release 
profile was used, that is Mt/M∞ ≤ 0.6 (Costa and Sousa Lobo, 2001). 
 
2.6. In vivo pharmacokinetic studies in Wistar rats 
Pharmacokinetic studies were performed in male Wistar rats (200-250 g) obtained from 
Harlan (Barcelona, Spain). Studies were approved by the Ethical Committee for Animal 
Experimentation of the University of Navarra (protocol number 028-11) in accordance 
with the European legislation on animal experiments. Before the oral administration of 
the formulations, animals were fasted overnight to avoid interference with the 
absorption, allowing free access to water. 
For the pharmacokinetic study, rats were randomly divided into 5 groups (n=6). The 
experimental groups were as follows: (i) quercetin aqueous suspension (Q-susp), (ii) 
quercetin solution in PEG 400:water (60:40 v/v) (Q-sol) (iii) quercetin-loaded casein 
nanoparticles (Q-NP) and (iv) quercetin-loaded casein nanoparticles containing HP-β-CD 
(Q-HPCD-NP). All of these formulations were orally administered with a blunt needle via 
into the stomach. As control, a group of animals received intravenously the solution of 
quercetin in the mixture of PEG 400 and water. In all cases, the dose of quercetin (orally 
or intravenously) was 25 mg/kg body weight. 
Blood samples were collected at set times after administration (0, 10 min, 30 min, 1, 2, 
4, 6, 8, 24 and 48 hours) in Microvette® 500K3E plasma tubes (SARSTEDT, Germany).  
Blood volume was recovered intraperitoneally with an equal volume of normal saline 
solution pre-heated at body temperature. Samples were immediately centrifuged at 
9,400 x g for 10 min and plasma aliquots were frozen at -80 °C until analysis. 
 
2.6.1. Determination of quercetin plasma concentration 
The amount of quercetin was determined in plasma by HPLC as described above using 
chlorzoxazone as internal standard. Prior the analysis, quercetin was extracted from 
plasma samples following a protocol previously described by Li and co-workers (Li et al., 
2009) with minor modifications. For sample preparation, an aliquot of 100 µL plasma 
sample was mixed with 25 µL internal standard solution (chlorzoxazone, 50 µg/mL in 
methanol), 125 µL methanol and 50 µL HCl (25% by vol.) for protein precipitation 
followed by vigorous shaking at 2500 rpm for 10 min. Then, samples were hydrolyzed in 
a water bath at 50°C for 15 min and were centrifuged at 10,000 rpm for 10 min. The 
obtained supernatants were filtered (Filter nylon, 0.45μL, Thermo scientific, Rockford, 
USA) and a 50 µL aliquot of each sample were injected onto the HPLC column.  
The same protocol was used for calibration and quality control standards preparation, 
using blank plasma and different solutions of quercetin in methanol. Calibration curves 
were designed over the range 70-5000 ng/mL (R2>0.999). Under these experimental 
conditions, the run time of quercetin was 13.9 min (detected at 370 nm) and the internal 
standard 12.6 min (detected at 303 nm). The limit of quantification was calculated as 
200 ng/mL. Linearity, accuracy and precision values during the same day (intraday assay) 
at low, medium and high concentrations of quercetin were within the acceptable limits 
(relative error and coefficient of variation less than 15%). 
 
2.6.2. Pharmacokinetic data analysis 
Quercetin plasma concentration was plotted against time, and pharmacokinetic 
analysis, was performed using a non-compartmental model with the WinNonlin 5.2 
software (Pharsight Corporation, USA). The following parameters were estimated: 
maximal serum concentration (Cmax), time in which Cmax is reached (Tmax), area under the 
concentration-time curve from time 0 to last time (AUC), mean residence time (MRT), 
clearance (Cl), volume of distribution (V) and half-life in the terminal phase (t1/2). 
Furthermore, the relative bioavailability (Fr) of quercetin was estimated by the following 
equation: 
 
Fr (%) = (AUCoral)/(AUCiv)  × 100     [Eq. 5] 
Where AUCiv and AUCoral are the areas under the curve for the intravenous and oral 
administrations, respectively. 
 
2.7. Statistical analysis 
Data are expressed as the mean ± standard deviation (SD) of at least three experiments. 
The non-parametric Kruskall-Wallis followed by Mann-Whitney U-test was used to 
investigate statistical differences. In all cases, p< 0.05 was considered to be statistically 





3.1. Optimization and preparation of quercetin-loaded nanoparticles 
For the optimization of the preparative process of quercetin-loaded nanoparticles, the 
flavonoid-to-cyclodextrin ratio and the time of incubation between the main 
components of the formulation (sodium caseinate, quercetin and HP-β-CD) before the 
formation of nanoparticles were evaluated. Figure 1 shows the influence of the 
incubation time and the quercetin-to-HP-β-CD ratio on the encapsulation efficiency and 
payload of the resulting nanoparticles. The highest loading was obtained with a time of 
incubation of 30 min (between the components of the formulation) and quercetin-to-
HP-β-CD ratios of either 1:1 or 1:2 by mol. Under these experimental conditions, the 
payload of the resulting nanoparticles was about 31 μg quercetin per mg nanoparticles 
with an encapsulation efficiency higher than 80%. Thus, the following experimental 
conditions were selected: a quercetin-to-cyclodextrin ratio of 1:1 by mol and a time of 
incubation of 30 minute. 
Table 1 summarises the main physico-chemical characteristics of the nanoparticles used 
in this study. The mean diameter of empty casein nanoparticles was smaller than those 
loaded with quercetin. On the other hand, the incorporation of HP-β-CD decreased the 
mean diameter of the quercetin-loaded nanoparticles from 251 nm (for Q-NP) to 171 
nm (for Q-HPCD-NP). In all cases, the polydispersity index was below 0.3, indicating 
homogeneous nanoparticle formulations, and the zeta potential was negative. This 
negative charge was slightly higher when quercetin was loaded in casein nanoparticles.  
Another important aspect to highlight was that the incorporation of HP-β-CD increased 
40% the quercetin loading in casein nanoparticles (22.3 µg/mg vs. 31.5 µg/mg). 
The morphological analysis by scanning electron microscopy (Figure 2) showed that 
quercetin-loaded casein nanoparticles consisted of homogeneous population of 
irregular shaped nanoparticles, with a mean size similar to that obtained by photon 
correlation spectroscopy. Q-NP (Figure 2A) displayed a smooth surface; however, the 
formulation containing the cyclodextrin displayed nanoparticles with a rough surface 
(Figure 2B). 
 
3.2. In vitro release profile 
The release of quercetin from casein nanoparticles was evaluated in simulated gastric 
and intestinal fluids (Figure 3). Overall, the release of quercetin appeared to be 
independent of the pH conditions and slightly more rapid when released from Q-NP than 
from Q-HPCD-NP. For the first 2 hours, under SGF, about 20% of the loaded quercetin 
was released from both nanoparticle formulations. Then, after 4 hours of incubation in 
SIF, the amount of quercetin released was around 80% of the total content in Q-NP and 
close to 60% from Q-HPCD-NP. In any way, from both nanoparticle formulations, 24 
hours after the beginning of the experiment, almost the total amount of the 
encapsulated quercetin was released from casein nanoparticles. 
The quercetin release data from both nanoparticles were fitted to the Korsmeyer-
Peppas model, obtaining “n” values close to 1 (Table 2). These data suggested that the 
quercetin release from nanoparticles involves a release mechanism ruled by an 
erosion/relaxation phenomenon of the matrix. The release data were fitted to the zero-
order model, obtaining good regression coefficients (r2> 0.98). In all cases, the release 
constants were slightly higher when quercetin was released from nanoparticles 
prepared in the absence of HP-β-CD than from Q-HPCD-NP. 
 
3.3. Pharmacokinetic study 
Figure 4 shows the plasma concentration-time profile of quercetin after the oral 
administration of a single dose in rats (25 mg/kg) formulated as solution in a mixture of 
PEG400 and water (60:40 by vol.), aqueous suspension or encapsulated in casein 
nanoparticles. From the oral administration of the aqueous solution (Q-sol), the 
quercetin levels in the plasma of animals increased rapidly during the first hour post-
administration when the Cmax was reached. Then, the amount of quercetin in plasma 
decreased slowly during the following hours. For the aqueous suspension (Q-susp), the 
plasma levels of the flavonoid were quite low and quercetin was only quantified in 
plasma during the first 4 hours post-administration. On the contrary, for nanoparticle 
formulations (Q-NP and Q-HPCD-NP), quercetin plasma levels were significantly higher 
and more sustained and prolonged in time than those observed for the conventional 
formulations (Q-sol and Q-susp). For Q-NP, these high levels of the flavonoid in plasma 
were quantified up to 24 hours post-administration, whereas, for Q-HPCD-NP, plasma 
levels were observed up to 72 hours post-administration. 
For comparative purposes and pharmacokinetic analysis, the PEG-water solution of 
quercetin was also iv administered (25 mg/kg). In this case, the data adjusted well to a 
non-compartimental model characterized by a rapid decrease in a biphasic way of 
quercetin plasma concentrations. Moreover, 8-h post administration, quercetin in 
plasma was no longer quantified (data not shown).  
Table 3 summarizes the pharmacokinetic parameters estimated during the analysis of 
the experimental data obtained after the administration of the different quercetin 
formulations to rats. The oral solution of quercetin provided an AUC value 10-times 
higher than that observed for the suspension of the flavonoid (Q-susp). For classical 
casein nanoparticles (Q-NP), the AUC value was about 3-times higher than for the oral 
solution of the flavonoid. Moreover, for Q-HPCD-NP, the AUC was the highest and 
represented 61 µg h/mL, about 10-fold higher than the value calculated for the oral 
solution of quercetin. The half-life and the mean residence time of quercetin in plasma 
were significantly higher when the flavonoid was administered in casein nanoparticles 
than formulated as solution or suspension. In a similar way, the volume of distribution 
of quercetin also increased when the flavonoid was encapsulated in casein 
nanoparticles, whereas its clearance was of the same order in all cases.  Finally, the 
relative oral bioavailability of quercetin when incorporated in casein nanoparticles 
ranged from 11% to 36% (for Q-NP and Q-HPCD-NP, respectively). However, for the oral 




Quercetin, due to its beneficial effects, has been proposed as an interesting compound 
for dietary supplementation and food fortification (Aherne and O ’brien, 2002; Dwyer et 
al., 2015; Lin et al., 2019). However, due to its low oral bioavailability, formulation 
alternatives are necessary to solve this drawback. Nanoencapsulation may be an 
interesting approach to both improve the absorption of the loaded compound and offer 
protection against degradation or inactivation during storage and/or after 
administration. Regarding food fortification (process of adding nutrients or bioactive 
components to edible products (Dwyer et al., 2015)), the material employed to produce 
these nanoparticles should be GRAS and, ideally, to be a constituent of the food matrix.  
Among others, milk-based products are considered as good vehicles for bioactive 
components because they are staple food for a large part of the population (Ganesan et 
al., 2014; Karam et al., 2013). In this context, casein-based nanoparticles would be 
appropriate carriers for fortification of dairy products.  
In our study, casein nanoparticles were prepared by a simple coacervation method 
followed by a purification step and a subsequently drying process in order to minimize 
the physico-chemical degradation of the flavonoid. The mean size of the quercetin-
loaded casein nanoparticles was about 170 nm with a zeta potential of -15 mV. 
Interestingly, the incorporation of HP-β-CD produced more homogeneous (decreased 
PDI, Table 1) and smaller nanoparticles, without affecting their surface negative charge 
properties. Furthermore, the incorporation of the oligosaccharide permitted us to 
significantly increase the quercetin loading (31 μg/mg vs. 22 μg/mg in the absence of 
the cyclodextrin). This payload is in line with other previous results reported by other 
authors using similar devices such as Eudragit® L (acrylic polymer) nanoparticles (Pool et 
al., 2012), PLGA nanocapsules (Ghosh et al., 2011) or solid lipid nanoparticles (Li et al., 
2009). 
On the other hand, the release of quercetin from casein nanoparticles appeared to be 
independent of the pH conditions and followed a zero-order kinetic. This fact could be 
explained by the entry of the aqueous medium inside the casein nanoparticles that 
induced the diffusion of quercetin by a release mechanism ruled by erosion/relaxation 
of the matrix. Surprisingly, the incorporation of the cyclodextrin to the casein 
nanoparticles slightly decreased the release rate of quercetin from the resulting 
nanocarriers. This finding would suggest that the oligosaccharide interacts with casein 
to form a more compact matrix that would delay the release of quercetin from 
nanoparticles. Some years ago, it was reported that β-cyclodextrin is capable of forming 
inclusion complex with β-casein (Lee and Fennema, 1991), and, thus, prevent its 
aggregation when warmed. In the same line, cyclodextrins have been proposed as 
stabilizers of therapeutic proteins in order to minimize aggregation phenomena (Serno 
et al., 2011). However, in this case, the interaction between the oligosaccharide 
molecules and the protein would yield to a compact and more resistant matrix to the 
erosion and/or relaxation that would occur in an aqueous environment. In any case, 
further investigations are necessary to elucidate the real mechanism of the interaction 
between cyclodextrin and casein in the nanoparticulate form. 
When quercetin was administered by the intravenous route as a solution of PEG400 and 
water, the profile of the curve was biphasic and similar to that published previously 
(Chen et al., 2005). The terminal half-life (t1/2) of the quercetin was 0.6 h and the MRT 
was calculated to be 1.57 h. The oral administration of the same solution of quercetin 
induced discrete plasma levels that were only quantified during the first 8 hours post-
administration. For this solution, the bioavailability of quercetin was calculated to be 
about 4%. This result is in line with the data obtained by Chen and co-workers, who 
described a quercetin bioavailability of 5% with a 15% HP-β-CD aqueous solution of the 
flavonoid in male Sprague-Dawley rats (Chen et al., 2005). When quercetin was loaded 
in nanoparticles and orally administered to rats, the plasma levels of the flavonoid were 
higher than those observed for the control oral formulations (Figure 4). The 
incorporation of HP-β-CD in casein nanoparticles produced a significant prolongation of 
the quercetin plasma levels up to 72 h. This result was also evidenced by the high half-
life (t1/2) and MRT of the flavonoid when administered in the casein nanoparticles (see 
Table 3). Under these circumstances, the relative oral bioavailability of quercetin was 
calculated to be close to 37% (nine times higher than for the control solution of the 
flavonoid). These prolonged and high levels of quercetin in plasma would be related to 
a combination of two phenomena. First, casein nanoparticles would conduct the cargo 
until the surface of the gut epithelium. The mucus-permeating properties of these 
carriers would facilitate both their arrival to the surface of the enterocytes and an 
increased residence time in close contact with the absorptive membrane. Second, the 
cargo would be released and the presence of HP-β-CD would disarm the intestinal efflux 
pumps and the enzymatic complex associated to the cytochrome P450 (Buggins et al., 
2007; Ishikawa et al., 2005; Takizawa et al., 2013; Zhang Y. et al., 2011). All together 
would permit the absorption of quercetin and its improved bioavailability when 
encapsulated in these casein nanoparticles. Alternatively, lymphatic absorption may be 
a supplementary factor that can also contribute to this improved bioavailability 
observed for quercetin (aglycone) when loaded in casein nanoparticles. Recently, it has 
been demonstrated that quercetin may be absorbed by both intestinal capillaries and 
lymphatic ducts (Chen et al., 2010; Murota and Terao, 2005). This is important because 
absorption via the lymphatic system avoids hepatic first-pass metabolism and would 




In summary, the preparation of casein nanoparticles in the presence of HP-β-CD appears 
to be a good option to load quercetin for both nutraceutical and pharmaceutical 
purposes. The resulting nanoparticles offer a zero-order release rate of the flavonoid 
when incubated in simulated fluids. In vivo, these casein nanoparticles produced high 
and sustained levels of quercetin for periods up to 72 hours and an oral relative 
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Figure 1. Influence of the incubation time (15, 30 and 60 min) and the quercetin-to-HP-
β-CD ratio (1:1, 1:2 and 1:3 by mol) on the flavonoid loading (line, left axis) and its 
encapsulation efficiency (bars, right axis). Data are expressed as the mean ± SD, n=3. 
 
Figure 2. Scanning electron microscopy (SEM) of casein nanoparticles. (A) Q-NP: 
quercetin-loaded casein nanoparticles; (B) Q-HPCD-NP: quercetin-loaded casein 
nanoparticles containing hydroxypropyl-β-cyclodextrin. 
 
Figure 3. In vitro release studies of quercetin-loaded in nanoparticles. Q-NP: quercetin-
loaded casein nanoparticles; Q-HPCD-NP: quercetin-loaded in casein nanoparticles 
containing HP-β-CD. Data are expressed as the mean ± SD, (n=3). 
 
Figure 4. Quercetin plasma concentration vs. time after the oral administration of the 
different formulations at a dose of 25 mg/kg. Q-susp: quercetin aqueous suspension; Q-
sol:  quercetin solution in a PEG400-water mixture; Q-NP:  quercetin-loaded casein 
nanoparticles; Q-HPCD-NP: quercetin-loaded casein nanoparticles in the presence of 
























Table 1. Physico-chemical characteristics of empty (NP and HPCD-NP) and quercetin-















NP 138±13 0.19±0.02 -11.9±0.9 - - 
HPCD-NP 141±3 0.17±0.01 -12.3±2.1 - - 
Q-NP 251±9 0.26±0.02 -14.3±1.1 22.3±0.3 75.4±0.9 





Table 2. Analysis of quercetin release from casein nanoparticles when incubated during 
the first two hours in SGF and, then, in SIF. 
 
 Korsmeyer-Peppas Zero-Order 
KKP (h –n) n R2 KZO (h-1) R2 
Q-NP 0.14±0.01 0.94±0.06 0.983 0.13±0.01 0.982 





Table 3. Pharmacokinetic parameters of quercetin calculated from either the intravenous or oral administration of a single dose of the 
flavonoid (25 mg/Kg) formulated as a solution, suspension or encapsulated in nanoparticles. Q-IV. Quercetin intravenous solution in a 
mixture of PEG400 and water; Q-susp: quercetin aqueous suspension; Q-sol: oral quercetin solution in a mixture of PEG400 and water; Q-
NP: quercetin-loaded casein nanoparticles; Q-HPCD-NP: quercetin-loaded casein nanoparticles in the presence of HP-β-CD. Data are 


















Q-IV 0.0±0.0 176±13.4 0.60±0.35 167±8.21 26.3±16.1 30.2±1.35 1.57±0.12 100 
Q-susp 1.0±0.0 0.37±0.08** 0.54±0.49** 0.55±0.25** 29.1±24.5** 45.3±19.0 1.22±0.35** 0.33 
Q-sol 0.60±0.22 1.40±0.41 3.51±1.97 6.77±2.20 146±78.9 29.2±0.91 4.86±0.55 4.10 
Q-NP 3.7±1.5** 2.20±0.40* 6.28±1.51* 19.6±4.12** 262±60.9** 29.0±0.92 7.78±1.68** 11.8 
Q-HPCD-NP 6.3±2.7** 1.89±1.05 28.41±7.35**+ 61.4±24.5**+ 893±137**+ 22.3±2.61 28.5±3.01**+ 36.8 
Cmax: peak plasma concentration; Tmax: time to reach plasma concentration; AUC: Area under the curve; t ½: half life of the terminal 
phase; V: Volume of distribution, Cl: Clearance; MRT: mean residence time Fr: relative oral bioavailability 
* Significant differences vs Q-sol (p<0.05) Mann-Whitney-U 
** Significant differences vs Q-sol (p<0.01) Mann-Whitney-U 
+ Significant differences vs Q-NP (p<0.01) Mann-Whitney-U
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